DGAP-News

RHÖN-KLINIKUM AG: Interim Report for the First Six Months of 2017

DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Half Year Results/Miscellaneous RHÖN-KLINIKUM AG: Interim Report for the First Six Months of 2017 03.08.2017 / 06:59 The issuer is solely responsible for the content of this announcement. Press Release

Interim Report for the First Six Months of 2017:
Corporate Focus on the Implementation of the Campus Concept and Digitalisation - Agreement in Separate Accounting offers new prospects for UKGM - After Ratification EBITDA for 2017 expected at the upper end of the estimated range

 

- 422,950 patients treated

- Revenues stand at Euro 598.4 million

- EBITDA is at Euro 50.2 million

- Outlook for 2017: Revenues between Euro 1.20 billion and Euro 1.23 billion,

  EBITDA between Euro 85 million and Euro 105 million

 

Bad Neustadt / Saale, 3rd August 2017

 

In the first six months of 2017 a total of 422,950 patients were treated in the RHÖN-KLINIKUM AG hospitals at the five different sites. Revenues stood at Euro 598.4 million with earnings before interest, taxes, depreciation and amortisation (EBITDA) at Euro 50.2 million.

 

Outlook

For the current financial year 2017 the Company expects revenues of between Euro 1.20 billion to Euro 1.23 billion. This is particularly adversely affected by the latest regulatory legislation, such as lower remuneration for special orthopaedic and cardiological services or the recently introduced discount for lower overheads in the area of additional services.

The Company expects EBITDA of between Euro 85 million and Euro 105 million for 2017. This includes negative effects in a low two-digit million figure for the corporate restructuring which was commenced at the beginning of the year and other imminent investments in the area of digital transformation. RHÖN-KLINIKUM AG currently assumes that the agreement in separate accounting for the university hospital in Giessen and Marburg (Universitätsklinikum Giessen und Marburg GmbH - UKGM) will be legally ratified in the second half of 2017. In that case, we expect EBITDA to be within the upper half of the range.